Evidence map›Paper›PMID 39086601›Full record

ArticleJournal of biotechnology and biomedicine2024

Extraction-Free Testing for SARS-CoV-2 in Nasal Swab and Saliva Samples on a Single High-Throughput Platform.

Yue Qiu, Ling Lu, Amanda Halven, Rachel Terrio, Sydney Yuldelson, Natalie Dougal, Filippo Galbo, Andrew Lu, Dexiang Gao, Bob Blomquist and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biotechnology and biomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yue QiuDepartment of Otolaryngology - Head & Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Ling LuDepartment of Otolaryngology - Head & Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Amanda HalvenLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.
Rachel TerrioLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.
Sydney YuldelsonLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.
Natalie DougalLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.
Filippo GalboLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.
Andrew LuDepartment of Otolaryngology - Head & Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Dexiang GaoDepartment of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora CO 80045, USA.
Bob BlomquistLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.
Jose P ZevallosDepartment of Otolaryngology - Head & Neck Surgery, Washington University School of Medicine, St. Louis, MO 63130, USA.
Shi-Long LuDepartment of Otolaryngology - Head & Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Xin YaoLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.
Brian L HarryLiquid Biopsy Laboratory, Summit Biolabs, Aurora, CO 80045, USA.

Funding

Validation of a saliva test using methylated microRNAs for head and neck cancer recurrenceUH2CA262045 · NCI · UNIVERSITY OF COLORADO DENVER · PI LU, SHI-LONG · 2021 to 2022
$368k
NCI NIH HHS UH2 CA262045
6 · The paper itself

Abstract

The COVID-19 pandemic introduced an urgent need for rapid and high-throughput testing for SARS-CoV-2. RNA extraction is a major bottleneck for RT-qPCR. We describe a semi-automated, extraction-free RT-qPCR assay for detection of SARS-CoV-2 in nasal swab and saliva samples on a single platform. With a limit of detection of 4 copies/mL, this laboratory developed test performed equivalently to established methods requiring nucleic acid extraction. Five technologists staffing two shifts per day (80 person-hours) processed more than 400,000 samples over 10 months. Patients opted to provide nasal swab samples (83.6%) more frequently than saliva (16.4%), creating the added challenge of producing swab collection kits. Real-world testing data indicated a higher frequency of SARS-CoV-2 detection in saliva (10.1%) compared to nasal swab (7.7%). This cost-effective and quickly scalable approach is suitable for pandemic preparedness planning related to surveillance and diagnostic testing.

Indexed as

COVID-19Nasal swabRNASaliva samplesSARS-CoV-2

Identifiers

PMID39086601
PMCPMC11290348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.